scholarly journals Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysis

2016 ◽  
Vol 11 (5) ◽  
pp. 1721-1733 ◽  
Author(s):  
YUAN-YUAN CHEN ◽  
LIN-WEI WANG ◽  
FANG-FANG CHEN ◽  
BI-BO WU ◽  
BIN XIONG
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Meta Analysis ◽  
Growth Factor Receptor ◽  
Breast Cancer Patients ◽  
Epidermal Growth ◽  
Administration Timing ◽  
Positive Breast Cancer

scholarly journals A Novel Prognostic Nomogram for the 2-year Survival in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Patients

2021 ◽  
Author(s):  
Mengdi Chen ◽  
Jiayi Wu ◽  
Deyue Liu ◽  
Weilin Chen ◽  
Weiguo Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Seer Database ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Epidermal Growth ◽  
Positive Breast Cancer

Abstract Background: Targeted therapies have largely improved prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Yet, disease can still progress rapidly for some patients in the first two years after diagnosis. Our study aimed to establish a nomogram model to predict the 2-year breast cancer-specific survival (BCSS) in early HER2-positive breast cancer patients. Methods: A total of 32,481 HER2-positive patients derived from Surveillance, Epidemiology, and End Results (SEER) database were included in the construction of nomogram. Concordance index (C-index) and calibration curve were used to evaluate the discrimination ability and predictive accuracy. We tested the model in 804 patients from Shanghai Jiao Tong University Breast Cancer Data Base (SJTU-BCDB). Results: Age, estrogen receptor (ER) status, progesterone receptor (PR) status, histologic type, T stage and N stage were selected to construct the nomogram according to multivariable analysis. The 2-year BCSS rate was 95% and 60% for patients at low risk (<8 points) and high risk (>13 points) respectively. The C-index of model derived from SEER database is 0.81 (95%CI 0.79-0.83). Sensitivity analysis was performed in patients after breast surgeries with the C-index of 0.81 (95%CI, 0.79-0.83). Validation in 804 patients from SJTU-BCDB showed respective C-index of 0.77 (95%CI, 0.62-0.92) in total population, 0.67 (95%CI 0.44-0.90) and 0.90 (95%CI 0.81-0.90) in patients who received anti-HER2 therapy or not. Discussion: The novel nomogram can predict the 2-year survival outcome in HER2-positive patients independent of receiving anti-HER2 therapy or not and allow clinicians to adjust therapeutic strategies for patients with higher risk.

Sign in / Sign up

Export Citation Format

Share Document